Columbia Laboratories to Host Analyst and Investor Day on January 28, 2010

LIVINGSTON, NJ, JANUARY 22, 2010 – Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that it will host an analyst and investor meeting on Thursday, January 28, 2010 from 9:00 am to 11:30 am ET in New York City.

The meeting will be comprised of an in-depth presentation entitled Changing the Practice of Medicine, highlighting the Company's current efforts in infertility, the background and status of its late-stage development project targeted at reducing the number of pre-term births, and followed by an update on the Company's strategy and plan going forward. This program will feature presentations by medical experts as well as Columbia's management team followed by a question and answer session with the speakers.

The meeting will be webcast live and may be accessed at http://www.cbrxir.com, under "Events."

About Columbia Laboratories

Columbia Laboratories, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the women’s healthcare and endocrinology markets that use its novel bioadhesive drug delivery technology. Columbia’s U.S. sales organization markets CRINONE^® 8% (progesterone gel) in the United States for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency and STRIANT^® (testosterone buccal system) for the treatment of hypogonadism in men. The Company’s partners market CRINONE, STRIANT and one other product to additional foreign and U.S. markets.

The Company is conducting, in collaboration with the NIH, the PREGNANT (PROCHIEVE^® Extending GestatioN A New Therapy) Study, a randomized, double blind, placebo controlled 450-patient Phase III clinical trial evaluating the ability of PROCHIEVE to reduce the risk of preterm birth in women with a cervical length between 1.0 and 2.0 centimeters as measured by transvaginal ultrasound at mid-pregnancy. The primary endpoint of the study is a reduction in the incidence of preterm birth at less than or equal to 32 weeks gestation vs. placebo. For more information, please visit www.columbialabs.com.